Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with Gemcitabine and Cisplatin in Malignant Mesothelioma
NCT00027703Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2001
- Primary completion
- May 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in malignant mesothelioma comparing Gem/Cis + Bevacizumab with Gem/Cis + Placebo (2 arms). Primary endpoint: Time to Disease Progression up to 9 years. Started Oct 2001; status: completed.
02
Drugs
bevacizumab
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT00027703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00027703.